TXN and breast cancer: Figure 5B shows no correlation between the patients (Pearson r = 0.08189; P = 0.2526), suggesting Trx1 is sustained in the serum of patients with breast cancer in a quite different manner from CA15-3 and also supporting Trx1 as an complementary and thus effective companion marker to CA15-3.